Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
The last day of the NBA regular season is Sunday. Expect chaos and lots of itI blocked off my driveway with £34 tool from ScrewfixWestfield Bondi Junction incident live updates: Heartbreak as mother of nineChinese experts help farmers in Cote d'Ivoire achieve bumper harvest of paddy riceSri Lanka extends demining body's tenure for landmine free nationTexas Gov. vows to expand border barriers amid standoff with White HouseMichigan voters go to polls for 2024 U.S. presidential primaryMichigan voters go to polls for 2024 U.S. presidential primaryCalifornia sees rise in tuberculosis casesDomestic terrorism, political violence seen as top threat to U.S. interests in 2024: survey
3.005s , 6574.609375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gleam news portal